Treatment for less severe<unk>  is supportive, addressing the symptoms like fever, muscle pain, or fatigue. Moderate<unk>  requires oxygen therapy and giving fluids and antihypotensive agents to raise blood pressure. For moderate to severe<unk> , the use of immunosuppressive agents like corticosteroids may be necessary, but judgment must be used to avoid negating the effect of drugs intended to activate the immune system. Tocilizumab, an anti-IL-6 monoclonal antibody, was FDA approved for steroid-refractory<unk>  based on retrospective case study data. Lenzilumab, an anti-GM-CSF monoclonal antibody, is also clinically proven to be effective at managing<unk><unk>  by reducing activation of myeloid cells and decreasing the production of IL-1, IL-6, MCP-1, MIP-1, and IP-10. Additionally, as a soluble<unk>  blockade, it will not increase serum levels of GM-CSF (a phenomenon seen with tocilizumab and IL-6). Although frequently used to treat severe<unk>  in people with ARDS, corticosteroids and NSAIDs have been evaluated in clinical trials and have shown no effect on lung mechanics, gas exchange, or beneficial outcome in early established ARDS.
Cytokine release syndrome
Macrophage activation syndrome
Systemic inflammatory response syndrome
Activation syndrome
Mast cell activation syndrome
Multiple organ dysfunction syndrome
SUNCT syndrome
SAHA syndrome